WO2016191289A3 - Biomarker for inflammatory disorders and uses thereof - Google Patents
Biomarker for inflammatory disorders and uses thereof Download PDFInfo
- Publication number
- WO2016191289A3 WO2016191289A3 PCT/US2016/033572 US2016033572W WO2016191289A3 WO 2016191289 A3 WO2016191289 A3 WO 2016191289A3 US 2016033572 W US2016033572 W US 2016033572W WO 2016191289 A3 WO2016191289 A3 WO 2016191289A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory disorders
- biomarker
- methods
- τίμρ
- aggrecan
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/53—Colony-stimulating factor [CSF]
- G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5428—IL-10
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5443—IL-15
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Disclosed herein are methods of screening, diagnosing, treating, evaluating efficacy, and/or monitoring inflammatory disorders such as rheumatoid arthritis and treatments for those inflammatory disorders by inhibiting or antagonizing IL-1 β and/or IL-17. The methods may involve measuring one or more biomarkers selected from collagen, aggrecan, ΤΊΜΡ-1, TRAP-5b, GM-CSF, CD4, CD40, MIP-1α, TNF, CD11b, IL-6, IL-10, IL-15, and IL-13Rα2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562165609P | 2015-05-22 | 2015-05-22 | |
US62/165,609 | 2015-05-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016191289A2 WO2016191289A2 (en) | 2016-12-01 |
WO2016191289A3 true WO2016191289A3 (en) | 2017-02-09 |
Family
ID=56121172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/033572 WO2016191289A2 (en) | 2015-05-22 | 2016-05-20 | Biomarker for inflammatory disorders and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016191289A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110124029B (en) * | 2019-04-19 | 2023-08-11 | 中山大学附属第六医院 | Application of IL-6R antibody and amniotic fluid stem cells in preparation of medicines for treating NEC |
WO2023164964A1 (en) * | 2022-03-01 | 2023-09-07 | 林俊 | Genetically engineered drug for treating brain injuries and preparation method therefor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
-
2016
- 2016-05-20 WO PCT/US2016/033572 patent/WO2016191289A2/en active Application Filing
Non-Patent Citations (4)
Title |
---|
G CHEVREL: "Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation", ANNALS OF THE RHEUMATIC DISEASES, vol. 61, no. 8, 1 August 2002 (2002-08-01), GB, pages 730 - 733, XP055313673, ISSN: 0003-4967, DOI: 10.1136/ard.61.8.730 * |
JIANYING QI ET AL: "A bispecific antibody against IL-1[beta] and IL-17A is beneficial for experimental rheumatoid arthritis", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 14, no. 4, 22 October 2012 (2012-10-22), pages 770 - 778, XP055140680, ISSN: 1567-5769, DOI: 10.1016/j.intimp.2012.10.005 * |
MARTINE CHABAUD ET AL: "The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 44, no. 6, 6 June 2001 (2001-06-06), pages 1293 - 1303, XP002631884, ISSN: 0004-3591, [retrieved on 20010606], DOI: 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T * |
QINGCUI LI ET AL: "Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 21, no. 1, 5 May 2014 (2014-05-05), pages 119 - 127, XP055195879, ISSN: 1567-5769, DOI: 10.1016/j.intimp.2014.04.018 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016191289A2 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3496301A4 (en) | Method by which terminal for supporting dual connection between e-utra and nr transmits and receives signal, and terminal for performing method | |
EP3567759A4 (en) | Method for reporting measurement data, and terminal therefor | |
GEP20197046B (en) | Substituted oxopyridine derivatives | |
WO2016077052A3 (en) | Evolution of proteases | |
WO2016145426A8 (en) | Methods for diagnosis of sepsis | |
WO2017106684A3 (en) | Antibodies specifically binding hla-dr and their uses | |
WO2018089693A3 (en) | Methods for determining and monitoring gastrointestinal inflammation | |
WO2015061634A3 (en) | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders | |
WO2015131151A3 (en) | Method and apparatus for determining markers of health by analysis of blood | |
WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
MX2022000893A (en) | Method of obtaining mitochondria from cells and obtained mitochondria. | |
EP3643001A4 (en) | Actively monitoring encrypted traffic by inspecting logs | |
WO2017076919A3 (en) | Methods for apolipoprotein detection | |
SG11201900126YA (en) | Object selection method and apparatus | |
WO2014036040A3 (en) | Methods for diagnosis, prognosis and methods of treatment | |
EP3532707A4 (en) | Methods and systems for sampling and/or analyzing fluid, such as production fluid from an oil and gas well | |
CA3073829A1 (en) | Methods and compositions for detecting and treating endometriosis | |
WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
WO2017029549A3 (en) | Methods, hosts, and reagents related thereto for production of isoprene and precursors thereof | |
EP3264093A4 (en) | Method for diagnosing diseases through oligomer analysis of abnormally aggregated proteins | |
WO2016191289A3 (en) | Biomarker for inflammatory disorders and uses thereof | |
MX2017013729A (en) | Specific detection of clusterin isoforms. | |
WO2016011265A3 (en) | Biomarkers for pin1-associated disorders | |
WO2016193945A3 (en) | Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders | |
WO2013084216A3 (en) | Heteroaryl compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16729107 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16729107 Country of ref document: EP Kind code of ref document: A2 |